Yarrow Bioscience, Inc. — Form 8-K/A
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On July 27, 2026, Yarrow Bioscience (formerly VYNE Therapeutics) completed a reverse merger and concurrent $200M financing ($100M pre-closing + $100M pre-closing financing). Yarrow in-licensed YB-101 (anti-TSHR antibody) from GenSci for $70M upfront in December 2025, with up to $1.295B in contingent milestones and tiered royalties (low-teens to low-mid teens). The company initiated a Phase 2a/2b GD trial in Q2 2026 with Phase 2a data expected H2 2027; cash runway estimated through 2028.
Why this rating
Material financing ($200M ≈ 6.3× company's $32M market cap) funds 2+ years of operations and de-risks near-term runway. Merger enables public capital access. YB-101 licensing ($70M upfront) represents major R&D commitment; contingent milestones add long-tail liability but signal confidence. Phase 2 initiation is normal progression. Relative to a $32M company, this is significant structural and financial change, though execution risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.